SENSEX NIFTY

Biosimilar

Mar 03, 2017 at 13:59 | Source: Moneycontrol.com
The court allowed the firm to make and sell Canmab, a cancer drug of the company. Stock was under pressure so far on the back of inspection reports. The management, earlier this morning, stated the inspections were expected as its dossiers were accepted by US FDA and EMA.
Feb 17, 2017 at 15:29 | Source: Moneycontrol.com
Biocon shares gained 2.6 percent to hit a record high of Rs 1,123 after the US health regulator USFDA has accepted pharma major Mylan's biologics licence application (BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim.
Feb 17, 2017 at 14:50 | Source: PTI
US health regulator USFDA hasaccepted pharma major Mylan's biologics licence application(BLA) for MYL-1401H, a proposed biosimilar Pegfilgrastim,Biocon and Mylan have said.
Feb 17, 2017 at 09:51 | Source: CNBC-TV18
Biocon Thursday announced the US Food and Drug Administration has accepted Mylans Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."
Feb 11, 2017 at 10:16 | Source: Moneycontrol.com
The company on Friday said it plans to spend about USD 80 million in next two years as it prepares to take the lead biosimilar molecule bevacizumab into clinical trial.
Feb 10, 2017 at 16:28 | Source: CNBC-TV18
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.
Feb 09, 2017 at 22:30 | Source: Moneycontrol.com
Aurobindo Pharma forayed into biosimilars with acquisition of four cell culture derived biosimilar products from Switzerland-based TL Biopharmaceutical AG. As part of the deal. TL will supply all the developmental data for four molecules and Aurobindo will develop and market these products globally.
Feb 09, 2017 at 22:04 | Source: PTI
Drug firm Aurobindo Pharma hasforayed into the biosimilar development space by acquiringfour cell culture derived products from Switzerland-based TLBiopharmaceutical AG.
Jan 25, 2017 at 11:02 | Source: CNBC-TV18
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Jan 12, 2017 at 09:44 | Source: Moneycontrol.com
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Messages on Biosimilar »

monk88888

New Member

54 Followers

Shilpa  

to see an end in sight-this could bleed the cashflows from standalone 5. Too much reliance on Oncology-what if T receptor cells technology picks up & wortks-would world walk away from onco drugs 6.They are behind the curve on biosimilars & lot of biosimilar manufacturers. have seen fast erosion

6.59 PM Apr 26th

Glenmark  

GBR 310 BIOSIMILARS...

1.58 PM Apr 25th

koppik

Gold Member

14 Followers

Biocon  

You are right, here is the news: http://t.in.com/27I7 "Korea%u2019s Green Cross acquired the local licensing rights to a Lantus biosimilar developed by India-based Biocon in November 2016, and has filed the drug for approval in Korea."

1.14 PM Apr 24th

andyin

New Member

6 Followers

Biocon  

korea s green cross acquired the local licensing rights to a lantus biosimilar developed by india-based biocon in november 2016, and has filed the drug for approval in korea.

12.27 PM Apr 24th

andyin

New Member

6 Followers

Biocon  

following appeared in korea herald newspaper of 17 april - looking ahead, two other biosimilars referencing lantus are also approaching commercialization in korea -- one developed by msd with partial funding from samsung bioepis, and another developed by india-based biocon and locally marketed

12.27 PM Apr 24th

savera_patn
a

Platinum Member

45 Followers

Biocon  

May launch at least one biosimilar in this calendar year and 2 more biosimilars in 2018... Total 3 launch by this fiscal year 03/2018 !!!

10.03 AM Apr 22nd

ramoohattia
ngdi

New Member

12 Followers

Aurobindo Pharm  

Auro target 810 (EPS41X20PE). Top-5 pharma co in India, Top-7 generic co in US, 421 filed ANDAs with 262 approvals. Revenue $2.2 Bn in 2016, target $3 Bn in 2018. EBIT 23.7% in 2017. 22 plants making niche orals, injectables, oncology, hormonals, penems, enzymes. Developing biosimilars in oncology

2.48 PM Apr 18th

Partager

New Member

2 Followers

Biocon  

dude.. mentioning biosimilar words doesn`t mean that letter is for biosimilars... its for some other drugs..

10.27 AM Apr 17th

boarder77

Platinum Member

114 Followers

Unichem Labs  

to handle the development of formulations for New Chemical Entities (NCEs). Further, the company has also established a biotech facility at Goa to invent, design, develop and commercialise biotech and biosimilar products. With a robust business model, seamless processes and innovative research, Unichem

7.05 PM Apr 7th

savera_patn
a

Platinum Member

45 Followers

Biocon  

1699 target is before announcement of Biosimilar approval... agar approval mil gaya to target for biocon will increase ):

10.44 AM Apr 7th

News across the web »
Jul 17, 2015 at 00:30 | Source: FirstPost
Follow us on
Available On